Blog
RSS FeedPosted by Michael Wonder on 06 Mar 2019
Canada should create new drug agency and list of medications available to everyone, council says
6 March 2019 - Canada should tiptoe in the direction of national pharmacare by creating a new drug agency and ...
Posted by Michael Wonder on 06 Mar 2019
Patient advocacy groups in Canada with ties to pharma are big boosters for government coverage
5 March 2019 - As the interplay between the pharmaceutical industry and patient advocacy groups undergoes stepped-up scrutiny, a new ...
Posted by Michael Wonder on 05 Mar 2019
Evaluating Canadians’ values for drug coverage decision making
2 March 2019 - Decision makers are facing growing challenges in prioritising drugs for reimbursement because of soaring drug costs and ...
Posted by Michael Wonder on 04 Mar 2019
Panel backs provincial funding for expensive drug to treat rare disease. But only for children.
4 March 2019 - Provincial governments should expand public funding for one of the world’s most expensive medications to cover ...
Posted by Michael Wonder on 03 Mar 2019
Biogen responds to CADTH’s updated recommendation regarding coverage for Spinraza
1 March 2019 - CADTH has expanded their recommendations for public reimbursement for SMA patients. ...
Posted by Michael Wonder on 28 Feb 2019
Drug prices aren’t a big problem, but Ottawa’s trying to control the market anyway
28 February 2019 - New policies will reduce access to new medicines for patients and impose massive new costs on taxpayers. ...
Posted by Michael Wonder on 27 Feb 2019
While some patients pay for biologic drugs, prison inmates get them for free
26 February 2019 - The Correctional Service of Canada spent more than $100 million over three-and-a-half years to provide inmates ...
Posted by Michael Wonder on 26 Feb 2019
Details of Doug Ford government’s health care overhaul, including new super agency, coming Tuesday
26 February 2019 - The Ontario government will announce its long-rumoured overhaul of the province’s health care system on Tuesday, ...
Posted by Michael Wonder on 26 Feb 2019
Are low-priced drugs becoming an endangered species?
26 February 2019 - The price of Canada’s top-selling patented drugs has increased by 800 per cent over 10 years. ...
Posted by Michael Wonder on 21 Feb 2019
How big pharma donations may influence public drug coverage
21 February 2019 - A new review of 372 patient group submissions to the CADTH – about whether new medicines should ...
Posted by Michael Wonder on 21 Feb 2019
Canada finds "insufficient evidence" that Janssen blocked biosimilar competition
21 February 2019 - Despite the fact that the investigation confirmed many of the allegations against Janssen, the bureau concluded that, ...
Posted by Michael Wonder on 20 Feb 2019
Updates for patients and communities
20 February 2019 - After spending the fall listening to patient groups and exploring how other organisations have involved patients ...
Posted by Michael Wonder on 20 Feb 2019
New drug landscape dominated by high cost medicines
19 February 2019 - The Patented Medicine Prices Review Board, through the National Prescription Drug Utilization Information System research initiative, ...
Posted by Michael Wonder on 14 Feb 2019
Quebec appeals court orders province to restore full coverage of rheumatoid-arthritis drug Remicade
13 February 2019 - Quebec’s highest court has ordered the provincial government to restore full public coverage of Remicade, an ...
Posted by Michael Wonder on 10 Feb 2019
How procurement judges the value of medical technologies: a review of health care tenders
8 February 2019 - Procurement's important role in healthcare decision making has encouraged criticism and calls for greater collaboration with health ...